ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingItem 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
As previously disclosed, on February 10, 2017, The Nasdaq Stock Market (“Nasdaq”) notified Anthera Pharmaceuticals, Inc. (“the Company”) that the bid price of the Company’s listed common stock was not in compliance with the continued listing requirements due to the bid price closing at less than $1.00 per share over the previous 30 consecutive business days. To regain compliance, the bid price of the Company’s common stock was required to close at $1.00 per share or more for a minimum of 10 consecutive business days. On May 16, 2017, the Company received notification from Nasdaq that bid price of Anthera’s common stock closed at more than $1.00 per share for 10 consecutive business days from May 1, 2017 through May 12, 2017, bringing the Company back in compliance with the minimum bid price listing requirement.
On May 15, 2017, the Company received a letter from Nasdaq informing the Company that its most recent Form 10-Q for the period ended March 31, 2017 reported stockholders’ equity fell below the minimum of $10,000,000 for continued inclusion under Listing Rule 5450(b)(1)(A). The letter stated that the Company may submit a plan to regain compliance to Nasdaq within 45 days of receipt of the letter. The Company intends to do so. If the plan is accepted, Nasdaq can grant an extension of up to 180 days for the Company to regain compliance. The letter has no immediate effect on the listing of the Company’s common stock.
About ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others. ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Recent Trading Information
ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) closed its last trading session down -0.13 at 1.76 with 379,708 shares trading hands.
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others. ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Recent Trading Information
ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) closed its last trading session down -0.13 at 1.76 with 379,708 shares trading hands.
